Products & ReviewLife Sciences
AVENIO Tumor Tissue CGP Kit
RocheAvailable: United States
The AVENIO Tumor Tissue CGP Kit is an in-house next-generation sequencing (NGS) research assay that provides comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue samples. Designed to match the content of the 324-gene FoundationOne® CDx panel, the kit leverages the proven technology of Foundation Medicine and Roche’s expertise to help your lab obtain reliable genomic insights.
- Designed to match the content of the 324-gene FoundationOne CDx panel, offering more insights and fewer missed opportunities than single biomarker or hot spot testing to help identify relevant alterations
- Detects all four mutation classes SNVs (single nucleotide variants), InDels (insertions or deletions), CNAs (copy number alterations) and Rearangements in a single DNA workflow1
- Identifies three genomic signatures: tumor mutational burden (TMB), microsatellite instability (MSI) and loss of heterozygosity (LOH)1
- Utilizes a streamlined, end-to-end DNA-only hybrid capture workflow from extraction to secondary analysis results in 5 days
- Provides an integrated solution that includes reagents and intuitive analysis and reporting to facilitate in-house adoption of a high performing NGS assay for oncology research